BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7736532)

  • 1. Tumor targeting in a murine tumor xenograft model with the (sFv')2 divalent form of anti-c-erbB-2 single-chain Fv.
    Huston JS; Adams GP; McCartney JE; Tai MS; Hudziak RM; Oppermann H; Stafford WF; Liu S; Fand I; Apell G
    Cell Biophys; 1994; 24-25():267-78. PubMed ID: 7736532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv.
    Adams GP; McCartney JE; Tai MS; Oppermann H; Huston JS; Stafford WF; Bookman MA; Fand I; Houston LL; Weiner LM
    Cancer Res; 1993 Sep; 53(17):4026-34. PubMed ID: 7689421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration.
    Adams GP; McCartney JE; Wolf EJ; Eisenberg J; Tai MS; Huston JS; Stafford WF; Bookman MA; Houston LL; Weiner LM
    Cancer Immunol Immunother; 1995 May; 40(5):299-306. PubMed ID: 7600561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptides.
    McCartney JE; Tai MS; Hudziak RM; Adams GP; Weiner LM; Jin D; Stafford WF; Liu S; Bookman MA; Laminet AA
    Protein Eng; 1995 Mar; 8(3):301-14. PubMed ID: 7479692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers.
    Adams GP; Tai MS; McCartney JE; Marks JD; Stafford WF; Houston LL; Huston JS; Weiner LM
    Clin Cancer Res; 2006 Mar; 12(5):1599-605. PubMed ID: 16533787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting c-erbB-2 expressing tumors using single-chain Fv monomers and dimers.
    Tai MS; McCartney JE; Adams GP; Jin D; Hudziak RM; Oppermann H; Laminet AA; Bookman MA; Wolf EJ; Liu S
    Cancer Res; 1995 Dec; 55(23 Suppl):5983s-5989s. PubMed ID: 7493381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced tumor specificity of 741F8-1 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation.
    Adams GP; McCartney JE; Wolf EJ; Eisenberg J; Huston JS; Bookman MA; Moldofsky P; Stafford WF; Houston LL; Weiner LM
    J Nucl Med; 1995 Dec; 36(12):2276-81. PubMed ID: 8523119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide.
    George AJ; Jamar F; Tai MS; Heelan BT; Adams GP; McCartney JE; Houston LL; Weiner LM; Oppermann H; Peters AM
    Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8358-62. PubMed ID: 7667295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library.
    Schier R; Marks JD; Wolf EJ; Apell G; Wong C; McCartney JE; Bookman MA; Huston JS; Houston LL; Weiner LM
    Immunotechnology; 1995 May; 1(1):73-81. PubMed ID: 9373335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiosensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo.
    Stackhouse MA; Buchsbaum DJ; Grizzle WE; Bright SJ; Olsen CC; Kancharla S; Mayo MS; Curiel DT
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):817-22. PubMed ID: 9845103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.
    Adams GP; Schier R; Marshall K; Wolf EJ; McCall AM; Marks JD; Weiner LM
    Cancer Res; 1998 Feb; 58(3):485-90. PubMed ID: 9458094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-chain Fv radioimmunotargeting.
    Huston JS; George AJ; Adams GP; Stafford WF; Jamar F; Tai MS; McCartney JE; Oppermann H; Heelan BT; Peters AM; Houston LL; Bookman MA; Wolf EJ; Weiner LM
    Q J Nucl Med; 1996 Sep; 40(3):320-33. PubMed ID: 8961808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody.
    Deshane J; Cabrera G; Grim JE; Siegal GP; Pike J; Alvarez RD; Curiel DT
    Gynecol Oncol; 1995 Oct; 59(1):8-14. PubMed ID: 7557620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments.
    Gilliland LK; Norris NA; Marquardt H; Tsu TT; Hayden MS; Neubauer MG; Yelton DE; Mittler RS; Ledbetter JA
    Tissue Antigens; 1996 Jan; 47(1):1-20. PubMed ID: 8929708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen recognition and targeted delivery by the single-chain Fv.
    Huston JS; Tai MS; McCartney J; Keck P; Oppermann H
    Cell Biophys; 1993; 22(1-3):189-224. PubMed ID: 7889539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical applications of single-chain antibodies.
    Huston JS; McCartney J; Tai MS; Mottola-Hartshorn C; Jin D; Warren F; Keck P; Oppermann H
    Int Rev Immunol; 1993; 10(2-3):195-217. PubMed ID: 8360586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.
    Yokota T; Milenic DE; Whitlow M; Wood JF; Hubert SL; Schlom J
    Cancer Res; 1993 Aug; 53(16):3776-83. PubMed ID: 8339291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
    McCall AM; Adams GP; Amoroso AR; Nielsen UB; Zhang L; Horak E; Simmons H; Schier R; Marks JD; Weiner LM
    Mol Immunol; 1999 May; 36(7):433-45. PubMed ID: 10449096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.
    Milenic DE; Yokota T; Filpula DR; Finkelman MA; Dodd SW; Wood JF; Whitlow M; Snoy P; Schlom J
    Cancer Res; 1991 Dec; 51(23 Pt 1):6363-71. PubMed ID: 1933899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.